1. Volume 143, Issue 3, Pages 608-618.e5 (September 2012)
Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir 
Fred Poordad, Jean–Pierre Bronowicki, Stuart C. Gordon, Stefan Zeuzem, Ira M. Jacobson, Mark S. Sulkowski, Thierry Poynard, Timothy R. Morgan, Cliona Molony, Lisa D. Pedicone, Heather L. Sings, Margaret H. Burroughs, Vilma Sniukiene, Navdeep Boparai, Venkata S. Goteti, Clifford A. Brass, Janice K. Albrecht, Bruce R. Bacon 
Gastroenterology 
Volume 143, Issue 3, Pages e5 (September 2012)
DOI: /j.gastro
Copyright © 2012 AGA Institute Terms and Conditions

2. Figure 1
SVR by IL-28B rs genotype for (A) previously untreated patients (SPRINT-2) and (B) previous treatment-failure patients (RESPOND-2). BOC, boceprevir.
Gastroenterology  , e5DOI: ( /j.gastro )
Copyright © 2012 AGA Institute Terms and Conditions

3. Figure 2
Median reductions in viral load from baseline on the basis of rs IL-28B genotype for (A) previously untreated patients (SPRINT-2) and (B) previous treatment-failure patients (RESPOND-2). Bars represent 25th and 75th percentiles. BOC, boceprevir.
Gastroenterology  , e5DOI: ( /j.gastro )
Copyright © 2012 AGA Institute Terms and Conditions

4. Figure 3
SVR by IL-28B rs genotype and HCV-RNA level at week 4 and by HCV-RNA detectability at week 8 for (A and B) previously untreated patients (SPRINT-2) and (C and D) previous treatment-failure patients (RESPOND-2). Patients with missing data at week 4 or week 8 are not included. BOC, boceprevir.
Gastroenterology  , e5DOI: ( /j.gastro )
Copyright © 2012 AGA Institute Terms and Conditions

5. Figure 4
Sustained virologic response in patients with poor response to interferon (<1 log10 decline in HCV RNA after a 4-week peginterferon-ribavirin lead-in) based on treatment week 8 response (log decline in viral load compared with baseline viral load, BOC RGT and BOC/PR48 arms combined). BOC, boceprevir.
Gastroenterology  , e5DOI: ( /j.gastro )
Copyright © 2012 AGA Institute Terms and Conditions

6. Supplementary Figure 1 Study design of SPRINT-2 and RESPOND-2.10,11
Gastroenterology  , e5DOI: ( /j.gastro )
Copyright © 2012 AGA Institute Terms and Conditions

7. Supplementary Figure 2
Analysis populations for IL-28B rs genomic distribution for SPRINT-2 (A) and RESPOND-2 (B). BOC, boceprevir.
Gastroenterology  , e5DOI: ( /j.gastro )
Copyright © 2012 AGA Institute Terms and Conditions